Cidara Therapeutics Company Insiders
| CDTX Stock | USD 22.47 0.63 2.73% |
Slightly above 67% of Cidara Therapeutics' corporate insiders are selling. The analysis of the overall insider sentiment regarding Cidara Therapeutics suggests that many insiders are alarmed. Cidara Therapeutics employs about 38 people. The company is managed by 16 executives with a total tenure of roughly 24 years, averaging almost 1.0 years of service per executive, having 2.38 employees per reported executive.
| Jeffrey Stein President Chief Executive and President and Executive Director |
Insider Sentiment 33
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-03-11 | Shane Ward | Disposed 1664 @ 21.96 | View | ||
| 2024-09-11 | Taylor Sandison | Disposed 924 @ 11.64 | View | ||
| 2024-06-07 | Jeffrey Stein | Acquired 8000 @ 13.21 | View |
Monitoring Cidara Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Cidara |
Cidara Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Cidara Therapeutics' future performance. Based on our forecasts, it is anticipated that Cidara will maintain a workforce of slightly above 50 employees by April 2025.Cidara Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4046) % which means that it has lost $0.4046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1959) %, meaning that it created substantial loss on money invested by shareholders. Cidara Therapeutics' management efficiency ratios could be used to measure how well Cidara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2025. Return On Capital Employed is likely to rise to -1.01 in 2025. At this time, Cidara Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 20.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 2.8 M in 2025.Common Stock Shares Outstanding is likely to rise to about 6.7 M in 2025, whereas Net Loss is likely to drop (28.2 M) in 2025.
Cidara Therapeutics Workforce Comparison
Cidara Therapeutics is rated second in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 231. Cidara Therapeutics retains roughly 38.0 in number of employees claiming about 16% of equities under Health Care industry.
Cidara Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cidara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cidara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cidara Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 2.0 | 4 | 2 | 216,900 | 3,437 |
| 2024-09-01 | 5.6667 | 17 | 3 | 1,967,905 | 11,877 |
| 2024-03-01 | 1.8 | 9 | 5 | 2,434,250 | 137,787 |
| 2023-09-01 | 1.0 | 2 | 2 | 60,000 | 37,262 |
| 2023-03-01 | 2.2 | 11 | 5 | 2,055,250 | 37,556 |
| 2022-09-01 | 0.2 | 1 | 5 | 50,000 | 118,478 |
| 2022-03-01 | 2.125 | 17 | 8 | 1,768,770 | 197,327 |
| 2021-12-01 | 1.0 | 7 | 7 | 117,863 | 47,863 |
| 2021-09-01 | 1.1818 | 13 | 11 | 1,190,950 | 357,990 |
| 2021-06-01 | 2.6667 | 8 | 3 | 140,000 | 3,239 |
| 2021-03-01 | 3.5 | 14 | 4 | 1,438,400 | 6,560 |
| 2020-03-01 | 1.5 | 12 | 8 | 1,102,847 | 52,683 |
| 2019-12-01 | 1.1818 | 13 | 11 | 253,123 | 390,267 |
| 2019-09-01 | 1.1 | 11 | 10 | 161,200 | 49,701 |
| 2019-03-01 | 5.0 | 15 | 3 | 699,670 | 25,880 |
| 2018-12-01 | 1.0 | 2 | 2 | 179,619 | 109,238 |
| 2018-09-01 | 0.4 | 2 | 5 | 24,000 | 19,123 |
| 2017-12-01 | 1.0 | 1 | 1 | 60,000 | 0.00 |
| 2017-03-01 | 2.5 | 10 | 4 | 595,400 | 44,000 |
| 2016-09-01 | 2.0 | 2 | 1 | 210,000 | 0.00 |
| 2015-06-01 | 1.1579 | 22 | 19 | 6,199,929 | 10,762,885 |
Cidara Therapeutics Notable Stakeholders
A Cidara Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cidara Therapeutics often face trade-offs trying to please all of them. Cidara Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cidara Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jeffrey Stein | Chief Executive and President and Executive Director | Profile | |
| Laura Navalta | Senior Vice President - Clinical Operations | Profile | |
| Les Tari | Vice President - Discovery Research | Profile | |
| Kevin Forrest | Founder, CFO, COO and Treasurer | Profile | |
| Shane Ward | COO Secretary | Profile | |
| Shane JD | COO Secretary | Profile | |
| Carol Waldo | VP Assurance | Profile | |
| Preetam MBA | Principal Officer | Profile | |
| James Balkovec | VP Research | Profile | |
| Taylor Sandison | Acting Chief Medical Officer | Profile | |
| SPHR CCP | Senior Culture | Profile | |
| Jim MBA | Chief Officer | Profile | |
| Leslie Tari | Chief Officer | Profile | |
| MD JD | Interim Development | Profile | |
| MPH MD | Chief Officer | Profile | |
| Frank MBA | Chief Officer | Profile |
About Cidara Therapeutics Management Performance
The success or failure of an entity such as Cidara Therapeutics often depends on how effective the management is. Cidara Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cidara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cidara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.79) | (0.83) | |
| Return On Capital Employed | (1.07) | (1.01) | |
| Return On Assets | (0.79) | (0.83) | |
| Return On Equity | (1.04) | (0.99) |
Please note, the imprecision that can be found in Cidara Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cidara Therapeutics. Check Cidara Therapeutics' Beneish M Score to see the likelihood of Cidara Therapeutics' management manipulating its earnings.
Cidara Therapeutics Workforce Analysis
Traditionally, organizations such as Cidara Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cidara Therapeutics within its industry.Cidara Therapeutics Manpower Efficiency
Return on Cidara Therapeutics Manpower
| Revenue Per Employee | 33.6K | |
| Revenue Per Executive | 79.7K | |
| Net Loss Per Employee | 4.5M | |
| Net Loss Per Executive | 10.6M | |
| Working Capital Per Employee | 4.2M | |
| Working Capital Per Executive | 10.1M |
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.